Unusual case of propofol-related infusion syndrome complicating severe COVID-19 ARDS

BMJ Case Rep. 2023 Feb 7;16(2):e249456. doi: 10.1136/bcr-2022-249456.

Abstract

An elderly man presenting with shortness of breath and hypoxaemia was admitted with acute hypoxic respiratory failure secondary to COVID-19 pneumonia. Due to worsening hypoxaemia, he was transferred to the intensive care unit and required mechanical ventilation. Propofol was infused at 1.5-4 mg/kg/hour. Within 48 hours of initiation, we noticed worsening metabolic acidosis, acute kidney injury, hyperkalaemia, hyperphosphataemia, hypertriglyceridaemia, elevated creatine kinase and elevated myoglobin levels. Suspecting propofol-related infusion syndrome (PRIS), we discontinued his propofol infusion immediately and initiated supportive measures. In 48 hours, there was a significant improvement in metabolic acidosis, hypertriglyceridaemia, rhabdomyolysis and renal function. The propofol infusion rate and cumulative propofol dosage (under 140 mg/kg) were well below levels associated with PRIS. COVID-19's pathogenesis, still under investigation, may have contributed to this presentation. It is imperative for clinicians to maintain a high degree of suspicion once propofol is initiated, regardless of the cumulative dose or rate of infusion.

Keywords: Acute renal failure; Adult intensive care; COVID-19; Drugs and medicines; Unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Acidosis*
  • Aged
  • COVID-19*
  • Humans
  • Hyperlipidemias*
  • Hypertriglyceridemia*
  • Male
  • Propofol Infusion Syndrome*
  • Propofol*
  • Respiratory Distress Syndrome*

Substances

  • Propofol